kr808.30
+ kr153.30 (23.40%)
End-of-day quote: 06/08/2022
CPSE:NOVO B

Novo Nordisk A/S (NOVO B)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide.

If you are interested in NOVO B stock information, you might also be interested in competitors like TSE:4568.

With a P/E ratio of 15.00, the stock appears relatively cheap compared to its index ^SPG1200 at the moment.

The market capitalization of Novo Nordisk A/S is currently at kr1,759.61 B. This places it among the high capitalized companies.

The book value reported in the balance sheet results in a P/B ratio of 27.65.

With one share of Novo Nordisk A/S investors achieved a dividend of kr12.85. This results in a very low dividend yield of 1.59%. In the last 20 years, the quarterly dividend has risen constantly.

For the risk analysis, the low beta factor should be noted, which is currently at a value of 0.25. The price of the stock CPSE:NOVO B is therefore subject to moderate fluctuations in relation to the overall market.

28.57% of NOVO B Stocks is owned by insiders.

For Wall Street analysts, a price target of kr678.96 is currently considered realistic.

CPSE:NOVO B has a 52 week range of kr498.25 - kr834.50 and is currently trading around kr808.30.

The low short sale ratio indicated that the value might increase in the foreseeable future.

5
Neutral
1
2
3
4
5
6
7
8
9
10
1M 3M YTD 1Y 2Y 5Y 10Y 20Y
P/E Ratio
23.0
Market Cap
1759.61B
LT Debt/Cap
0.01%
Price-to-book Ratio
27.65
Earnings
08/04/2022
Dividend
kr12.85
Div Yld
1.59%
Dividend Growth
20 Years
Beta
0.25
Short Interest
0.00%
Forecast 1Y
-17.30%
Analyst Price Target
kr678.96
LTG 5Y
6.75%
52 week range
kr498.25 - kr834.50
Country